Novo Nordisk Flaunts Tresiba To Outsmart Sanofi’s Lantus In India
This article was originally published in PharmAsia News
Executive Summary
After widening the gap with competitors in the insulin market by a huge margin, Novo Nordisk is preparing to launch Tresiba and take a shot at the long-acting basal insulin market, a stronghold preserved by Sanofi globally. Will Tresiba firmly establish Novo Nordisk as the unquestionable insulin leader?